Comparative Pharmacology
Head-to-head clinical analysis: ERYTHROMYCIN LACTOBIONATE versus WYAMYCIN E.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHROMYCIN LACTOBIONATE versus WYAMYCIN E.
ERYTHROMYCIN LACTOBIONATE vs WYAMYCIN E
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin lactobionate inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing the translocation of peptides. It may also act as a motilin receptor agonist, enhancing gastrointestinal motility.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
1-4 g/day IV divided every 6 hours; maximum 4 g/day. Infuse over 20-60 minutes.
500 mg intramuscularly or intravenously every 12 hours; or 1 gram every 24 hours for severe infections.
None Documented
None Documented
Terminal elimination half-life: 1.4-2.0 hours in adults with normal renal function. In patients with anuria, half-life may be prolonged up to 4.8-6.0 hours.
2.5 hours (increased to 5-8 hours in neonates and up to 24-48 hours in anuria).
Primarily biliary excretion (80-90% as unchanged drug and metabolites); renal excretion accounts for 10-15% of the dose. Fecal elimination is minimal (<5%).
Primarily renal (60-80% unchanged) via glomerular filtration; biliary/fecal <5%.
Category A/B
Category C
Macrolide Antibiotic
Macrolide Antibiotic